Monsenso ASOCSE:MONSO +4.57%29 PS Ratio is 3.08 as of Jul. 13, 2026, which is 72% above its 10-year median of 1.79. GuruFocus rates OCSE:MONSO with a GF Score™ of 29/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 659 Healthcare Providers & Services companies, Monsenso AS ranks worse than 71.62% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Monsenso AS's share price is kr0.366.
Monsenso AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.12. Hence, Monsenso AS's PS Ratio for today is 3.08.
The historical rank and industry rank for Monsenso AS's PS Ratio or its related term are showing as below:
OCSE:MONSO'
s PS Ratio Range Over the Past 10 Years
Min: 0.71 Med: 1.79 Max: 18
Current: 3.08
During the past 9 years, Monsenso AS's highest PS Ratio was 18.00. The lowest was 0.71. And the median was 1.79.
OCSE:MONSO's PS Ratio is ranked worse than 71.62% of 659
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs OCSE:MONSO: 3.08
Monsenso AS revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Monsenso AS was -23.70% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -19.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -23.60% per year.
During the past 9 years, Monsenso AS's highest 3-Year average Revenue per Share Growth Rate was -17.50% per year. The lowest was -48.90% per year. And the median was -25.20% per year.
Back to Basics: PS Ratio
Monsenso AS (OCSE:MONSO) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Monsenso AS PS Ratio Related Terms
Monsenso AS PS Ratio Historical Data
* Premium members only.
The historical data trend for Monsenso AS's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:MONSO vs VEEV, BTSG, TEM: PS Ratio Comparison
For the Health Information Services subindustry, Monsenso AS's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Monsenso AS PS Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Monsenso AS's PS Ratio distribution charts can be found below:
* The bar in red indicates where Monsenso AS's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Monsenso AS's Share Price of today is kr0.366.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Monsenso AS's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was kr0.12.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Monsenso AS (OCSE:MONSO) has a PS Ratio of 3.08 as of Jul. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Monsenso AS and its competitors. This is 72% above median its historical median of 1.79. Over the past decade, Monsenso AS's PS Ratio has ranged from 0.71 to 18.00. According to the industry distribution chart, Monsenso AS ranks #472 out of 659 companies in the Healthcare Providers & Services industry, placing it in the top 71.6%.
Is Monsenso AS's PS Ratio too high?
Monsenso AS's current PS Ratio of 3.08 is 72% above median its 10-year median of 1.79. Over the past 10 years, this metric has ranged from a low of 0.71 to a high of 18.00. The Healthcare Providers & Services industry median PS Ratio is 1.47. Monsenso AS's value of 3.08 is 109.5% above this industry median. Based on the distribution chart, Monsenso AS ranks #472 out of 659 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Monsenso AS has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's PS Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Monsenso AS ranks #472 out of 659 companies for PS Ratio. This places Monsenso AS in the lower half of its industry. The industry median PS Ratio is 1.47. Monsenso AS's value of 3.08 is 109.5% above this benchmark. Historically, Monsenso AS's own PS Ratio has ranged from 0.71 to 18.00 over the past decade. While the company's 10-year median is 1.79 vs. the industry median of 1.47, Monsenso AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Healthcare Providers & Services company?
The median PS Ratio among Healthcare Providers & Services companies is 1.47, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Monsenso AS's current PS Ratio of 3.08 is 109.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Monsenso AS and its competitors. For the Healthcare Providers & Services industry, the median PS Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Monsenso AS's current PS Ratio is 3.08, which is 72% above median its own 10-year median of 1.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.37 — trading 144% above its estimated fair value. The current PS Ratio is 3.08, which is 72% above median its 10-year median of 1.79 and 109.5% above the Healthcare Providers & Services industry median of 1.47. Monsenso AS's overall GF Score™ is 29/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current PS Ratio is 3.08 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?
Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued.
The current stock price of kr0.37 is trading 144% above its estimated GF Value™ of kr0.15.
GuruFocus considers Monsenso AS to be Significantly Overvalued.
Key valuation signals for OCSE:MONSO:
PS Ratio: 3.08 (72% above median its 10-year median of 1.79)
GF Value™: kr0.15 vs. price of kr0.37 (144% above fair value)
Industry Position: 109.5% above the Healthcare Providers & Services median (#472 of 659)
No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
29GF Score
Get the complete analysis for OCSE:MONSO
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:MONSO has been successfully added to your 
